JOSEPH ALUDWIGJOSEPH A LUDWIG9383LUDWIG, JOSEPH AAssociate Professorprns:coAuthorOfcoauthor ofFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:similarTosimilar toprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierAddressvivo:address1address line 1vivo:addressCitycityvivo:addressPostalCodepostal codevivo:addressStatestate or provincevivo:authorInAuthorshipselected publicationsvivo:authorRankauthor rank in publicationAuthorshipDepartmentDivisionvivo:hasResearchArearesearch areasvivo:hrJobTitleHR job titleInformation Resourcevivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcevivo:mailingAddressmailing addressvivo:personInPositionpositionsPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPerson1901 East RoadHouston77054-3005TXAuthorship 1812314Authorship 1820386Authorship 1853302Authorship 1855307Authorship 1876348Authorship 1885633Authorship 19287511Authorship 19508511Authorship 1956701317999412Boersma BJ, Reimers M, Yi M, Ludwig JA, Luke BT, Stephens RM, Yfantis HG, Lee DH, Weinstein JN, Ambs SInternational journal of cancerA stromal gene signature associated with inflammatory breast cancer. Int J Cancer. 2008 Mar 15; 122(6):1324-32.Int J Cancer2008-03-15T00:00:002008A stromal gene signature associated with inflammatory breast cancer.19533369Subbiah V, Anderson P, Lazar AJ, Burdett E, Raymond K, Ludwig JACurrent treatment options in oncologyEwing's sarcoma: standard and experimental treatment options. Curr Treat Options Oncol. 2009 Apr; 10(1-2):126-40.Curr Treat Options Oncol2009-06-17T00:00:002009Ewing's sarcoma: standard and experimental treatment options.20187067Reynoso D, Subbiah V, Trent JC, Guadagnolo BA, Lazar AJ, Benjamin R, Pollock RE, Ludwig JAJournal of surgical oncologyNeoadjuvant treatment of soft-tissue sarcoma: a multimodality approach. J Surg Oncol. 2010 Mar 15; 101(4):327-33.J Surg Oncol2010-03-15T00:00:002010Neoadjuvant treatment of soft-tissue sarcoma: a multimodality approach.20864919Subbiah V, Ludwig JAClinical advances in hematology & oncology : H&OReview: Ewing sarcoma treatment: a role for bisphosphonates? Clin Adv Hematol Oncol. 2010 Jul; 8(7):503-4.Clin Adv Hematol Oncol2010-07-01T00:00:002010Review: Ewing sarcoma treatment: a role for bisphosphonates?21480200Park MS, Patel SR, Ludwig JA, Trent JC, Conrad CA, Lazar AJ, Wang WL, Boonsirikamchai P, Choi H, Wang X, Benjamin RS, Araujo DMCancerActivity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor. Cancer. 2011 Nov 01; 117(21):4939-47.Cancer2011-04-08T00:00:002011Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor.24448245Satelli A, Mitra A, Cutrera JJ, Devarie M, Xia X, Ingram DR, Dibra D, Somaiah N, Torres KE, Ravi V, Ludwig JA, Kleinerman ES, Li SCancer researchUniversal marker and detection tool for human sarcoma circulating tumor cells. Cancer Res. 2014 Mar 15; 74(6):1645-50.Cancer Res2014-01-21T00:00:002014Universal marker and detection tool for human sarcoma circulating tumor cells.Gynecological Oncology & Reproductive MedicineHematopathologyInvestigational Cancer TherapeuticsLeukemiaPediatricsSarcoma Medical OncologyMD AndersonHESHAMAMINHESHAM AMIN8968AMIN, HESHAMProfessorVIVEKSUBBIAHVIVEK SUBBIAH9518SUBBIAH, VIVEKAssistant ProfessorHAGOP MKANTARJIANHAGOP M KANTARJIAN8501KANTARJIAN, HAGOP MProfessorROBERTCOLEMANROBERT COLEMAN9184COLEMAN, ROBERTProfessor5.264210.0102212259research areas3.172780.024499179coauthor of68.76511.738960similar to1176selected publicationsEUGENIE SKLEINERMANEUGENIE S KLEINERMAN8489KLEINERMAN, EUGENIE SProfessorSHREYASKUMARPATELSHREYASKUMAR PATEL8514PATEL, SHREYASKUMARProfessorALEXANDERLAZARALEXANDER LAZAR9206LAZAR, ALEXANDERProfessorAuthorship 2230881Authorship 234097116651436Ludwig JA, Szak?cs G, Martin SE, Chu BF, Cardarelli C, Sauna ZE, Caplen NJ, Fales HM, Ambudkar SV, Weinstein JN, Gottesman MMCancer researchSelective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer. Cancer Res. 2006 May 01; 66(9):4808-15.Cancer Res2006-05-01T00:00:002006Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer.24212944Ludwig JA, Lamhamedi-Cherradi SE, Lee HY, Naing A, Benjamin RCancersDual targeting of the insulin-like growth factor and collateral pathways in cancer: combating drug resistance. Cancers (Basel). 2011 Jul 26; 3(3):3029-54.Cancers (Basel)2011-07-26T00:00:002011Dual targeting of the insulin-like growth factor and collateral pathways in cancer: combating drug resistance.25772182Pan HY, Morani A, Wang WL, Hess KR, Paulino AC, Ludwig JA, Lin PP, Daw NC, Mahajan AInternational journal of radiation oncology, biology, physicsPrognostic factors and patterns of relapse in ewing sarcoma patients treated with chemotherapy and r0 resection. Int J Radiat Oncol Biol Phys. 2015 Jun 01; 92(2):349-57.Int J Radiat Oncol Biol Phys2015-03-12T00:00:002015Prognostic factors and patterns of relapse in ewing sarcoma patients treated with chemotherapy and r0 resection.Authorship 2484291Authorship 2501672Authorship 2507481Authorship 2551343Authorship 2598651116239904Ludwig JA, Weinstein JNNature reviews. CancerBiomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer. 2005 Nov; 5(11):845-56.Nat Rev Cancer2005-11-01T00:00:002005Biomarkers in cancer staging, prognosis and treatment selection.17234123Gottesman MM, Ludwig J, Xia D, Szak?cs GDiscovery medicineDefeating drug resistance in cancer. Discov Med. 2006 Feb; 6(31):18-23.Discov Med2006-02-01T00:00:002006Defeating drug resistance in cancer.18525337Ludwig JACurrent opinion in oncologyEwing sarcoma: historical perspectives, current state-of-the-art, and opportunities for targeted therapy in the future. Curr Opin Oncol. 2008 Jul; 20(4):412-8.Curr Opin Oncol2008-07-01T00:00:002008Ewing sarcoma: historical perspectives, current state-of-the-art, and opportunities for targeted therapy in the future.19843850T?rk D, Hall MD, Chu BF, Ludwig JA, Fales HM, Gottesman MM, Szak?cs GCancer researchIdentification of compounds selectively killing multidrug-resistant cancer cells. Cancer Res. 2009 Nov 01; 69(21):8293-301.Cancer Res2009-10-20T00:00:002009Identification of compounds selectively killing multidrug-resistant cancer cells.23477833Schwartz GK, Tap WD, Qin LX, Livingston MB, Undevia SD, Chmielowski B, Agulnik M, Schuetze SM, Reed DR, Okuno SH, Ludwig JA, Keedy V, Rietschel P, Kraft AS, Adkins D, Van Tine BA, Brockstein B, Yim V, Bitas C, Abdullah A, Antonescu CR, Condy M, Dickson MA, Vasudeva SD, Ho AL, Doyle LA, Chen HX, Maki RGThe Lancet. OncologyCixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial. Lancet Oncol. 2013 Apr; 14(4):371-82.Lancet Oncol2013-03-08T00:00:002013Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial.Authorship 2682951Authorship 2688974Authorship 270564718778559Ludwig JACurrent oncology reportsPersonalized therapy of sarcomas: integration of biomarkers for improved diagnosis, prognosis, and therapy selection. Curr Oncol Rep. 2008 Jul; 10(4):329-37.Curr Oncol Rep2008-07-01T00:00:002008Personalized therapy of sarcomas: integration of biomarkers for improved diagnosis, prognosis, and therapy selection.20092396Burdett E, Kasper FK, Mikos AG, Ludwig JATissue engineering. Part B, ReviewsEngineering tumors: a tissue engineering perspective in cancer biology. Tissue Eng Part B Rev. 2010 Jun; 16(3):351-9.Tissue Eng Part B Rev2010-06-01T00:00:002010Engineering tumors: a tissue engineering perspective in cancer biology.22465830Naing A, LoRusso P, Fu S, Hong DS, Anderson P, Benjamin RS, Ludwig J, Chen HX, Doyle LA, Kurzrock RClinical cancer research : an official journal of the American Association for Cancer ResearchInsulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors. Clin Cancer Res. 2012 May 01; 18(9):2625-31.Clin Cancer Res2012-03-31T00:00:002012Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors.Authorship 2791246Authorship 2866365Authorship 29118210Authorship 2912014Authorship 2965604Authorship 2968022Authorship 30344410Authorship 312713212652501Gehling G, Ludwig J, Schmidt A, Daniel WG, Werner DCatheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & InterventionsPercutaneous occlusion of femoral artery pseudoaneurysm by para-aneurysmal saline injection. Catheter Cardiovasc Interv. 2003 Apr; 58(4):500-4.Catheter Cardiovasc Interv2003-04-01T00:00:002003Percutaneous occlusion of femoral artery pseudoaneurysm by para-aneurysmal saline injection.23272660Wang WL, Katz D, Araujo DM, Ravi V, Ludwig JA, Trent JC, Patel SR, Lin PP, Guadagnolo A, L?pez-Terrada D, Dei Tos AP, Lewis VO, Lev D, Pollock RE, Zagars GK, Benjamin RS, Madewell JE, Lazar AJClinical sarcoma researchExtensive adipocytic maturation can be seen in myxoid liposarcomas treated with neoadjuvant doxorubicin and ifosfamide and pre-operative radiation therapy. Clin Sarcoma Res. 2012 Dec 29; 2(1):25.Clin Sarcoma Res2012-12-29T00:00:002012Extensive adipocytic maturation can be seen in myxoid liposarcomas treated with neoadjuvant doxorubicin and ifosfamide and pre-operative radiation therapy.25119929Jiang Y, Subbiah V, Janku F, Ludwig JA, Naing A, Benjamin RS, Brown RE, Anderson P, Kurzrock RPloS oneNovel secondary somatic mutations in Ewing's sarcoma and desmoplastic small round cell tumors. PLoS One. 2014; 9(8):e93676.PLoS One2014-08-13T00:00:002014Novel secondary somatic mutations in Ewing's sarcoma and desmoplastic small round cell tumors.25109853Lamhamedi-Cherradi SE, Santoro M, Ramammoorthy V, Menegaz BA, Bartholomeusz G, Iles LR, Amin HM, Livingston JA, Mikos AG, Ludwig JAAdvanced drug delivery reviews3D tissue-engineered model of Ewing's sarcoma. Adv Drug Deliv Rev. 2014 Dec 15; 79-80:155-71.Adv Drug Deliv Rev2014-08-07T00:00:0020143D tissue-engineered model of Ewing's sarcoma.25869102Jiang Y, Ludwig J, Janku FCancer treatment reviewsTargeted therapies for advanced Ewing sarcoma family of tumors. Cancer Treat Rev. 2015 May; 41(5):391-400.Cancer Treat Rev2015-03-27T00:00:002015Targeted therapies for advanced Ewing sarcoma family of tumors.25964201Lamhamedi-Cherradi SE, Menegaz BA, Ramamoorthy V, Aiyer RA, Maywald RL, Buford AS, Doolittle DK, Culotta KS, O'Dorisio JE, Ludwig JAMolecular cancer therapeuticsAn Oral Formulation of YK-4-279: Preclinical Efficacy and Acquired Resistance Patterns in Ewing Sarcoma. Mol Cancer Ther. 2015 Jul; 14(7):1591-604.Mol Cancer Ther2015-05-11T00:00:002015An Oral Formulation of YK-4-279: Preclinical Efficacy and Acquired Resistance Patterns in Ewing Sarcoma.26240353Santoro M, Lamhamedi-Cherradi SE, Menegaz BA, Ludwig JA, Mikos AGProceedings of the National Academy of Sciences of the United States of AmericaFlow perfusion effects on three-dimensional culture and drug sensitivity of Ewing sarcoma. Proc Natl Acad Sci U S A. 2015 Aug 18; 112(33):10304-9.Proc Natl Acad Sci U S A2015-08-03T00:00:002015Flow perfusion effects on three-dimensional culture and drug sensitivity of Ewing sarcoma.74Professor10Assistant Professor14Associate ProfessorRAVINRATANRAVIN RATAN11853RATAN, RAVINAssistant Professor23576741Fong EL, Lamhamedi-Cherradi SE, Burdett E, Ramamoorthy V, Lazar AJ, Kasper FK, Farach-Carson MC, Vishwamitra D, Demicco EG, Menegaz BA, Amin HM, Mikos AG, Ludwig JAProceedings of the National Academy of Sciences of the United States of AmericaModeling Ewing sarcoma tumors in vitro with 3D scaffolds. Proc Natl Acad Sci U S A. 2013 Apr 16; 110(16):6500-5.Proc Natl Acad Sci U S A2013-04-01T00:00:002013Modeling Ewing sarcoma tumors in vitro with 3D scaffolds.20855800Vadhan-Raj S, Trent J, Patel S, Zhou X, Johnson MM, Araujo D, Ludwig JA, O'Roark S, Gillenwater AM, Bueso-Ramos C, El-Naggar AK, Benjamin RSAnnals of internal medicineSingle-dose palifermin prevents severe oral mucositis during multicycle chemotherapy in patients with cancer: a randomized trial. Ann Intern Med. 2010 Sep 21; 153(6):358-67.Ann Intern Med2010-09-21T00:00:002010Single-dose palifermin prevents severe oral mucositis during multicycle chemotherapy in patients with cancer: a randomized trial.Authorship 842567Authorship 842921Authorship 844195Authorship 846410Authorship 848305Authorship 857139Authorship 857359Authorship 867896Proceedings of the National Academy of Sciences of the United States of AmericaFlow perfusion effects on three-dimensional culture and drug sensitivity of Ewing sarcoma. Proceedings of the National Academy of Sciences of the United States of America. 112:10304-10309.Flow perfusion effects on three-dimensional culture and drug sensitivity of Ewing sarcomaOncotargetThe second European interdisciplinary Ewing sarcoma research summit - A joint effort to deconstructing the multiple layers of a complex disease. Oncotarget. 7:8613-8624.The second European interdisciplinary Ewing sarcoma research summit - A joint effort to deconstructing the multiple layers of a complex diseaseCancer MedicineSurvival of patients with metastatic leiomyosarcoma. Cancer Medicine. 5:3437-3444.Survival of patients with metastatic leiomyosarcomaSoft tissue sarcomas. 653-666.Soft tissue sarcomasEwing sarcoma family of tumors. 235-244.Ewing sarcoma family of tumorsEwing's sarcoma spheroids as a 3-D model of In Vivo biology useful for high-throughput preclinical screening of antineoplastic drug candidates. Ewing's sarcoma spheroids as a 3-D model of In Vivo biology useful for high-throughput preclinical screening of antineoplastic drug candidatesOncotargetValidation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials. Oncotarget. 7:64421-64430.Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trialsScientific ReportsEvaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies. Scientific Reports. 6.Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved TherapiesD012509Disorders49417100.464973SarcomaD012512Disorders1744060.728911Sarcoma, EwingD001859Disorders67825640.39737Bone NeoplasmsAuthorship 9049957Authorship 90683514Authorship 91182321Authorship 91447114Authorship 9158068Authorship 91730712Authorship 91886013Authorship 9202807Authorship 92100917Authorship 9218167Authorship 9222978Authorship 92519620Authorship 9257989Authorship 9288467Authorship 930744926802024Kovar H, Amatruda J, Brunet E, Burdach S, Cidre-Aranaz F, de Alava E, Dirksen U, van der Ent W, Grohar P, Gr?newald TG, Helman L, Houghton P, Iljin K, Korsching E, Ladanyi M, Lawlor E, Lessnick S, Ludwig J, Meltzer P, Metzler M, Mora J, Moriggl R, Nakamura T, Papamarkou T, Radic Sarikas B, R?dini F, Richter GH, Rossig C, Schadler K, Sch?fer BW, Scotlandi K, Sheffield NC, Shelat A, Snaar-Jagalska E, Sorensen P, Stegmaier K, Stewart E, Sweet-Cordero A, Szuhai K, Tirado OM, Tirode F, Toretsky J, Tsafou K, ?ren A, Zinovyev A, Delattre OOncotargetThe second European interdisciplinary Ewing sarcoma research summit--A joint effort to deconstructing the multiple layers of a complex disease. Oncotarget. 2016 Feb 23; 7(8):8613-24.Oncotarget2016-02-23T00:00:002016The second European interdisciplinary Ewing sarcoma research summit--A joint effort to deconstructing the multiple layers of a complex disease.27576731Lamhamedi-Cherradi SE, Menegaz BA, Ramamoorthy V, Vishwamitra D, Wang Y, Maywald RL, Buford AS, Fokt I, Skora S, Wang J, Naing A, Lazar AJ, Rohren EM, Daw NC, Subbiah V, Benjamin RS, Ratan R, Priebe W, Mikos AG, Amin HM, Ludwig JAJournal of the National Cancer InstituteIGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma. J Natl Cancer Inst. 2016 12; 108(12).J Natl Cancer Inst2016-08-30T00:00:002016IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma.27486883Livingston JA, Hess KR, Naing A, Hong DS, Patel S, Benjamin RS, Ludwig JA, Conley A, Herzog CE, Anderson P, Meric-Bernstam F, Kurzrock R, Subbiah VOncotargetValidation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials. Oncotarget. 2016 Sep 27; 7(39):64421-64430.Oncotarget2016-09-27T00:00:002016Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials.27748430Subbiah V, Hess KR, Khawaja MR, Wagner MJ, Tang C, Naing A, Fu S, Janku F, Piha-Paul S, Tsimberidou AM, Herzog CE, Ludwig JA, Patel S, Ravi V, Benjamin RS, Meric-Bernstam F, Hong DSScientific reportsEvaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies. Sci Rep. 2016 10 17; 6:35448.Sci Rep2016-10-17T00:00:002016Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies.27882721Wang Z, Shi N, Naing A, Janku F, Subbiah V, Araujo DM, Patel SR, Ludwig JA, Ramondetta LM, Levenback CF, Ramirez PT, Piha-Paul SA, Hong D, Karp DD, Tsimberidou AM, Meric-Bernstam F, Fu SCancer medicineSurvival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience. Cancer Med. 2016 12; 5(12):3437-3444.Cancer Med2016-11-23T00:00:002016Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience.27923328Santoro M, Menegaz BA, Lamhamedi-Cherradi SE, Molina ER, Wu D, Priebe W, Ludwig JA, Mikos AGTissue engineering. Part AModeling Stroma-Induced Drug Resistance in a Tissue-Engineered Tumor Model of Ewing Sarcoma. Tissue Eng Part A. 2017 01; 23(1-2):80-89.Tissue Eng Part A2017-01-01T00:00:002017Modeling Stroma-Induced Drug Resistance in a Tissue-Engineered Tumor Model of Ewing Sarcoma.28377484Subbiah V, Meyer C, Zinner R, Meric-Bernstam F, Zahurak ML, O'Connor A, Roszik J, Shaw K, Ludwig JA, Kurzrock R, Azad NAClinical cancer research : an official journal of the American Association for Cancer ResearchPhase Ib/II Study of the Safety and Efficacy of Combination Therapy with Multikinase VEGF Inhibitor Pazopanib and MEK Inhibitor Trametinib In Advanced Soft Tissue Sarcoma. Clin Cancer Res. 2017 08 01; 23(15):4027-4034.Clin Cancer Res2017-04-04T00:00:002017Phase Ib/II Study of the Safety and Efficacy of Combination Therapy with Multikinase VEGF Inhibitor Pazopanib and MEK Inhibitor Trametinib In Advanced Soft Tissue Sarcoma.28710342Wagner MJ, Gopalakrishnan V, Ravi V, Livingston JA, Conley AP, Araujo D, Somaiah N, Zarzour MA, Ratan R, Wang WL, Patel SR, Lazar A, Ludwig JA, Benjamin RSThe oncologistVincristine, Ifosfamide, and Doxorubicin for Initial Treatment of Ewing Sarcoma in Adults. Oncologist. 2017 10; 22(10):1271-1277.Oncologist2017-07-14T00:00:002017Vincristine, Ifosfamide, and Doxorubicin for Initial Treatment of Ewing Sarcoma in Adults.29138631Higham CS, Steinberg SM, Dombi E, Perry A, Helman LJ, Schuetze SM, Ludwig JA, Staddon A, Milhem MM, Rushing D, Jones RL, Livingston M, Goldman S, Moertel C, Wagner L, Janhofer D, Annunziata CM, Reinke D, Long L, Viskochil D, Baker L, Widemann BCSarcomaSARC006: Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated Chemotherapy-Naive Malignant Peripheral Nerve Sheath Tumors. Sarcoma. 2017; 2017:8685638.Sarcoma2017-09-12T00:00:002017SARC006: Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated Chemotherapy-Naive Malignant Peripheral Nerve Sheath Tumors.29626752Hayes-Jordan AA, Ma X, Menegaz BA, Lamhamedi-Cherradi SE, Kingsley CV, Benson JA, Camacho PE, Ludwig JA, Lockworth CR, Garcia GE, Craig SLNeoplasia (New York, N.Y.)Efficacy of ONC201 in Desmoplastic Small Round Cell Tumor. Neoplasia. 2018 05; 20(5):524-532.Neoplasia2018-04-05T00:00:002018Efficacy of ONC201 in Desmoplastic Small Round Cell Tumor.29383611Hayes-Jordan AA, Coakley BA, Green HL, Xiao L, Fournier KF, Herzog CE, Ludwig JA, McAleer MF, Anderson PM, Huh WWAnnals of surgical oncologyDesmoplastic Small Round Cell Tumor Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Results of a Phase 2 Trial. Ann Surg Oncol. 2018 Apr; 25(4):872-877.Ann Surg Oncol2018-01-30T00:00:002018Desmoplastic Small Round Cell Tumor Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Results of a Phase 2 Trial.29212731Menegaz BA, Cuglievan B, Benson J, Camacho P, Lamhamedi-Cherradi SE, Leung CH, Warneke CL, Huh W, Subbiah V, Benjamin RS, Patel S, Daw N, Hayes-Jordan A, Ludwig JAThe oncologistClinical Activity of Pazopanib in Patients with Advanced Desmoplastic Small Round Cell Tumor. Oncologist. 2018 03; 23(3):360-366.Oncologist2017-12-06T00:00:002017Clinical Activity of Pazopanib in Patients with Advanced Desmoplastic Small Round Cell Tumor.29871905Subbiah V, Lamhamedi-Cherradi SE, Cuglievan B, Menegaz BA, Camacho P, Huh W, Ramamoorthy V, Anderson PM, Pollock RE, Lev DC, Qiao W, McAleer MF, Benjamin RS, Patel S, Herzog CE, Daw NC, Feig BW, Lazar AJ, Hayes-Jordan A, Ludwig JAClinical cancer research : an official journal of the American Association for Cancer ResearchMultimodality Treatment of Desmoplastic Small Round Cell Tumor: Chemotherapy and Complete Cytoreductive Surgery Improve Patient Survival. Clin Cancer Res. 2018 10 01; 24(19):4865-4873.Clin Cancer Res2018-06-05T00:00:002018Multimodality Treatment of Desmoplastic Small Round Cell Tumor: Chemotherapy and Complete Cytoreductive Surgery Improve Patient Survival.30420447Puerto-Camacho P, Amaral AT, Lamhamedi-Cherradi SE, Menegaz BA, Castillo-Ecija H, Ord??ez JL, Dom?nguez S, Jordan-Perez C, Diaz-Martin J, Romero-P?rez L, Lopez-Alvarez M, Civantos-Jubera G, Robles-Fr?as MJ, Biscuola M, Ferrer C, Mora J, Cuglievan B, Schadler K, Seifert O, Kontermann R, Pfizenmaier K, Sim?n L, Fabre M, Carcaboso ?M, Ludwig JA, de ?lava EClinical cancer research : an official journal of the American Association for Cancer ResearchPreclinical Efficacy of Endoglin-Targeting Antibody-Drug Conjugates for the Treatment of Ewing Sarcoma. Clin Cancer Res. 2019 04 01; 25(7):2228-2240.Clin Cancer Res2018-11-12T00:00:002018Preclinical Efficacy of Endoglin-Targeting Antibody-Drug Conjugates for the Treatment of Ewing Sarcoma.30733229Subbiah V, Anderson PM, Kairemo K, Hess K, Huh WW, Ravi V, Daw NC, Somaiah N, Ludwig JA, Benjamin RS, Chawla S, Hong DS, Meric-Bernstam F, Ravizzini G, Kleinerman E, Macapinlac H, Rohren EClinical cancer research : an official journal of the American Association for Cancer ResearchAlpha Particle Radium 223 Dichloride in High-risk Osteosarcoma: A Phase I Dose Escalation Trial. Clin Cancer Res. 2019 07 01; 25(13):3802-3810.Clin Cancer Res2019-02-07T00:00:002019Alpha Particle Radium 223 Dichloride in High-risk Osteosarcoma: A Phase I Dose Escalation Trial.D023822Procedures1242680.803109Tissue EngineeringPathologyD058405Disorders42850.901112Desmoplastic Small Round Cell TumorAuthorship 9558911531542501Molina ER, Chim LK, Salazar MC, Mehta SM, Menegaz BA, Lamhamedi-Cherradi SE, Satish T, Mohiuddin S, McCall D, Zaske AM, Cuglievan B, Lazar AJ, Scott DW, Grande-Allen JK, Ludwig JA, Mikos AGActa biomaterialiaMechanically tunable coaxial electrospun models of YAP/TAZ mechanoresponse and IGF-1R activation in osteosarcoma. Acta Biomater. 2019 12; 100:38-51.Acta Biomater2019-09-19T00:00:002019Mechanically tunable coaxial electrospun models of YAP/TAZ mechanoresponse and IGF-1R activation in osteosarcoma.Authorship 977924432057288Molina ER, Chim LK, Barrios S, Ludwig JA, Mikos AGTissue engineering. Part B, ReviewsModeling the Tumor Microenvironment and Pathogenic Signaling in Bone Sarcoma. Tissue Eng Part B Rev. 2020 06; 26(3):249-271.Tissue Eng Part B Rev2020-02-14T00:00:002020Modeling the Tumor Microenvironment and Pathogenic Signaling in Bone Sarcoma.32565716Parkes A, Urquiola E, Bhosale P, Lin H, Watson K, Wang WL, Feig B, Torres K, Roland CL, Conley AP, Zarzour M, Livingston JA, Ratan R, Ludwig J, Araujo DM, Ravi V, Benjamin RS, Patel S, Somaiah NSarcomaPET/CT Imaging as a Diagnostic Tool in Distinguishing Well-Differentiated versus Dedifferentiated Liposarcoma. Sarcoma. 2020; 2020:8363986.Sarcoma2020-05-29T00:00:002020PET/CT Imaging as a Diagnostic Tool in Distinguishing Well-Differentiated versus Dedifferentiated Liposarcoma.Authorship 9937082732630797Amin HM, Morani AC, Daw NC, Lamhamedi-Cherradi SE, Subbiah V, Menegaz BA, Vishwamitra D, Eskandari G, George B, Benjamin RS, Patel S, Song J, Lazar AJ, Wang WL, Kurzrock R, Pappo A, Anderson PM, Schwartz GK, Araujo D, Cuglievan B, Ratan R, McCall D, Mohiuddin S, Livingston JA, Molina ER, Naing A, Ludwig JACancersIGF-1R/mTOR Targeted Therapy for Ewing Sarcoma: A Meta-Analysis of Five IGF-1R-Related Trials Matched to Proteomic and Radiologic Predictive Biomarkers. Cancers (Basel). 2020 Jul 02; 12(7).Cancers (Basel)2020-07-02T00:00:002020IGF-1R/mTOR Targeted Therapy for Ewing Sarcoma: A Meta-Analysis of Five IGF-1R-Related Trials Matched to Proteomic and Radiologic Predictive Biomarkers.Authorship 10027751033050651Tarek N, Said R, Andersen CR, Suki TS, Foglesong J, Herzog CE, Tannir NM, Patel S, Ratan R, Ludwig JA, Daw NCCancersPrimary Ewing Sarcoma/Primitive Neuroectodermal Tumor of the Kidney: The MD Anderson Cancer Center Experience. Cancers (Basel). 2020 Oct 11; 12(10).Cancers (Basel)2020-10-11T00:00:002020Primary Ewing Sarcoma/Primitive Neuroectodermal Tumor of the Kidney: The MD Anderson Cancer Center Experience.Authorship 100834820Authorship 10085181033408328Lamhamedi-Cherradi SE, Mohiuddin S, Mishra DK, Krishnan S, Velasco AR, Vetter AM, Pence K, McCall D, Truong DD, Cuglievan B, Menegaz BA, Utama B, Daw NC, Molina ER, Zielinski RJ, Livingston JA, Gorlick R, Mikos AG, Kim MP, Ludwig JACancer gene therapyTranscriptional activators YAP/TAZ and AXL orchestrate dedifferentiation, cell fate, and metastasis in human osteosarcoma. Cancer Gene Ther. 2021 12; 28(12):1325-1338.Cancer Gene Ther2021-01-06T00:00:002021Transcriptional activators YAP/TAZ and AXL orchestrate dedifferentiation, cell fate, and metastasis in human osteosarcoma.33418729Trachtenberg JE, Santoro M, Williams C, Piard CM, Smith BT, Placone JK, Menegaz BA, Molina ER, Lamhamedi-Cherradi SE, Ludwig JA, Sikavitsas VI, Fisher JP, Mikos AGACS biomaterials science & engineeringEffects of Shear Stress Gradients on Ewing Sarcoma Cells Using 3D Printed Scaffolds and Flow Perfusion. ACS Biomater Sci Eng. 2018 Feb 12; 4(2):347-356.ACS Biomater Sci Eng2017-02-15T00:00:002017Effects of Shear Stress Gradients on Ewing Sarcoma Cells Using 3D Printed Scaffolds and Flow Perfusion.Authorship 10094951333463239Molina ER, Chim LK, Salazar MC, Koons GL, Menegaz BA, Ruiz-Velasco A, Lamhamedi-Cherradi SE, Vetter AM, Satish T, Cuglievan B, Smoak MM, Scott DW, Ludwig JA, Mikos AGACS biomaterials science & engineering3D Tissue-Engineered Tumor Model for Ewing's Sarcoma That Incorporates Bone-like ECM and Mineralization. ACS Biomater Sci Eng. 2020 01 13; 6(1):539-552.ACS Biomater Sci Eng2019-12-13T00:00:0020193D Tissue-Engineered Tumor Model for Ewing's Sarcoma That Incorporates Bone-like ECM and Mineralization.Authorship 10112241133575859Parkes A, Wang WL, Patel S, Leung CH, Lin H, Conley AP, Somaiah N, Araujo DM, Zarzour M, Livingston JA, Ludwig J, Roland CL, Ravi V, Benjamin RS, Ratan RBreast cancer research and treatmentOutcomes of systemic therapy in metastatic phyllodes tumor of the breast. Breast Cancer Res Treat. 2021 Apr; 186(3):871-882.Breast Cancer Res Treat2021-02-11T00:00:002021Outcomes of systemic therapy in metastatic phyllodes tumor of the breast.Authorship 1016294133852792Ludwig JA, Meyers PA, Dirksen UThe New England journal of medicineEwing's Sarcoma. N Engl J Med. 2021 Apr 15; 384(15):1476.N Engl J Med2021-04-15T00:00:002021Ewing's Sarcoma.Authorship 103827815Authorship 10394959Authorship 104123619Authorship 1041528335128664Nassif EF, Cope B, Traweek R, Witt RG, Erstad DJ, Scally CP, Thirasastr P, Zarzour MA, Ludwig J, Benjamin R, Bishop AJ, Guadagnolo BA, Ingram D, Wani K, Wang WL, Lazar AJ, Torres KE, Hunt KK, Feig BW, Roland CL, Somaiah N, Keung EZInternational journal of cancerReal-world use of palbociclib monotherapy in retroperitoneal liposarcomas at a large volume sarcoma center. Int J Cancer. 2022 06 15; 150(12):2012-2024.Int J Cancer2022-02-18T00:00:002022Real-world use of palbociclib monotherapy in retroperitoneal liposarcomas at a large volume sarcoma center.35228656Bhalla AD, Landers SM, Singh AK, Landry JP, Yeagley MG, Myerson GSB, Delgado-Baez CB, Dunnand S, Nguyen T, Ma X, Bolshakov S, Menegaz BA, Lamhamedi-Cherradi SE, Mao X, Song X, Lazar AJ, McCutcheon IE, Slopis JM, Ludwig JA, Lev DC, Rai K, Torres KELaboratory investigation; a journal of technical methods and pathologyExperimental models of undifferentiated pleomorphic sarcoma and malignant peripheral nerve sheath tumor. Lab Invest. 2022 06; 102(6):658-666.Lab Invest2022-02-28T00:00:002022Experimental models of undifferentiated pleomorphic sarcoma and malignant peripheral nerve sheath tumor.35284040Molina ER, Chim LK, Lamhamedi-Cherradi SE, Mohiuddin S, McCall D, Cuglievan B, Krishnan S, Porter RW, Ingram DR, Wang WL, Lazar AJ, Scott DW, Truong DD, Daw NC, Ludwig JA, Mikos AGOncotargetCorrelation of nuclear pIGF-1R/IGF-1R and YAP/TAZ in a tissue microarray with outcomes in osteosarcoma patients. Oncotarget. 2022; 13:521-533.Oncotarget2022-03-09T00:00:002022Correlation of nuclear pIGF-1R/IGF-1R and YAP/TAZ in a tissue microarray with outcomes in osteosarcoma patients.35251924Truong DD, Lamhamedi-Cherradi SE, Ludwig JAJournal of bone oncologyTargeting the IGF/PI3K/mTOR pathway and AXL/YAP1/TAZ pathways in primary bone cancer. J Bone Oncol. 2022 Apr; 33:100419.J Bone Oncol2022-02-24T00:00:002022Targeting the IGF/PI3K/mTOR pathway and AXL/YAP1/TAZ pathways in primary bone cancer.Authorship 10433801435379887Wu CC, Beird HC, Lamhamedi-Cherradi SE, Soeung M, Ingram D, Truong DD, Porter RW, Krishnan S, Little L, Gumbs C, Zhang J, Titus M, Genovese G, Ludwig JA, Lazar AJ, Hayes-Jordan A, Futreal PANPJ precision oncologyMulti-site desmoplastic small round cell tumors are genetically related and immune-cold. NPJ Precis Oncol. 2022 Apr 04; 6(1):21.NPJ Precis Oncol2022-04-04T00:00:002022Multi-site desmoplastic small round cell tumors are genetically related and immune-cold.Authorship 1045237135517059Ludwig JA, Van Tine BJournal of bone oncologyCommentary: A Special Edition in bone sarcoma. J Bone Oncol. 2022 Jun; 34:100426.J Bone Oncol2022-04-20T00:00:002022Commentary: A Special Edition in bone sarcoma.Authorship 1046134335582528Cherradi-Lamhamedi SE, Truong D, Ludwig JACancer drug resistance (Alhambra, Calif.)Understanding sarcoma drug resistance one cell at a time. Cancer Drug Resist. 2022; 5(1):90-92.Cancer Drug Resist2022-01-19T00:00:002022Understanding sarcoma drug resistance one cell at a time.Authorship 10470353035650195Lamhamedi-Cherradi SE, Maitituoheti M, Menegaz BA, Krishnan S, Vetter AM, Camacho P, Wu CC, Beird HC, Porter RW, Ingram DR, Ramamoorthy V, Mohiuddin S, McCall D, Truong DD, Cuglievan B, Futreal PA, Velasco AR, Anvar NE, Utama B, Titus M, Lazar AJ, Wang WL, Rodriguez-Aguayo C, Ratan R, Livingston JA, Rai K, MacLeod AR, Daw NC, Hayes-Jordan A, Ludwig JANature communicationsThe androgen receptor is a therapeutic target in desmoplastic small round cell sarcoma. Nat Commun. 2022 06 01; 13(1):3057.Nat Commun2022-06-01T00:00:002022The androgen receptor is a therapeutic target in desmoplastic small round cell sarcoma.Authorship 105489016Authorship 106068214Authorship 105819314Authorship 10553442436288393Moyers JT, Pestana RC, Roszik J, Hong DS, Naing A, Fu S, Piha-Paul S, Yap TA, Karp D, Rodon J, Livingston A, Zarzour MA, Ravi V, Patel S, Benjamin RS, Ludwig J, Herzog C, Ratan R, Somaiah N, Conley A, Gorlick R, Meric-Bernstam F, Subbiah VClinical cancer research : an official journal of the American Association for Cancer ResearchExamining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102). Clin Cancer Res. 2023 01 17; 29(2):401-409.Clin Cancer Res2023-01-17T00:00:002023Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102).36151848Thirasastr P, Lin H, Amini B, Wang WL, Cloutier JM, Nassif EF, Keung EZ, Roland CL, Feig B, Araujo D, Benjamin RS, Conley AP, Livingston JA, Ludwig J, Patel S, Ratan R, Ravi V, Zarzour MA, Zhou X, Somaiah NCancer medicineRetrospective evaluation of the role of gemcitabine-docetaxel in well-differentiated and dedifferentiated liposarcoma. Cancer Med. 2023 02; 12(4):4282-4293.Cancer Med2022-09-24T00:00:002022Retrospective evaluation of the role of gemcitabine-docetaxel in well-differentiated and dedifferentiated liposarcoma.36313661Lazcano R, Barreto CM, Salazar R, Carapeto F, Traweek RS, Leung CH, Gite S, Mehta J, Ingram DR, Wani KM, Vu KT, Parra ER, Lu W, Zhou J, Witt RG, Cope B, Thirasastr P, Lin HY, Scally CP, Conley AP, Ratan R, Livingston JA, Zarzour AM, Ludwig J, Araujo D, Ravi V, Patel S, Benjamin R, Wargo J, Wistuba II, Somaiah N, Roland CL, Keung EZ, Solis L, Wang WL, Lazar AJ, Nassif EFFrontiers in oncologyThe immune landscape of undifferentiated pleomorphic sarcoma. Front Oncol. 2022; 12:1008484.Front Oncol2022-10-12T00:00:002022The immune landscape of undifferentiated pleomorphic sarcoma.Authorship 10676512937058010Carmagnani Pestana R, Moyers JT, Roszik J, Sen S, Hong DS, Naing A, Herzog CE, Fu S, Piha-Paul SA, Rodon J, Yap TA, Karp DD, Tsimberidou AM, Pant S, Zarzour MA, Ratan R, Ravi V, Benjamin RS, Lazar AJ, Wang WL, Daw N, Gill JB, Harrison DJ, Lewis VO, Roland CL, Patel SR, Livingston JA, Somaiah N, Ludwig JA, Conley AP, Hamerschlak N, Gorlick R, Meric-Bernstam F, Subbiah VClinical cancer research : an official journal of the American Association for Cancer ResearchImpact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101). Clin Cancer Res. 2023 05 01; 29(9):1708-1718.Clin Cancer Res2023-05-01T00:00:002023Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101).Authorship 10734471437254069Truong DD, Lamhamedi-Cherradi SE, Porter RW, Krishnan S, Swaminathan J, Gibson A, Lazar AJ, Livingston JA, Gopalakrishnan V, Gordon N, Daw NC, Navin NE, Gorlick R, Ludwig JABMC cancerDissociation protocols used for sarcoma tissues bias the transcriptome observed in single-cell and single-nucleus RNA sequencing. BMC Cancer. 2023 May 31; 23(1):488.BMC Cancer2023-05-31T00:00:002023Dissociation protocols used for sarcoma tissues bias the transcriptome observed in single-cell and single-nucleus RNA sequencing.Authorship 1079730737745374Truong DD, Weistuch C, Murgas KA, Deasy JO, Mikos AG, Tannenbaum A, Ludwig JbioRxiv : the preprint server for biologyMapping the Single-cell Differentiation Landscape of Osteosarcoma. bioRxiv. 2023 Sep 14.bioRxiv2023-09-14T00:00:002023Mapping the Single-cell Differentiation Landscape of Osteosarcoma.Authorship 10844861037986851Magrath JW, Goldberg IN, Truong DD, Hartono AB, Sampath SS, Jackson CE, Ghosh A, Cardin DL, Zhang H, Ludwig JA, Lee SBbioRxiv : the preprint server for biologyEnzalutamide Induces Cytotoxicity in Desmoplastic Small Round Cell Tumor Independent of the Androgen Receptor. bioRxiv. 2023 Nov 06.bioRxiv2023-11-06T00:00:002023Enzalutamide Induces Cytotoxicity in Desmoplastic Small Round Cell Tumor Independent of the Androgen Receptor.Authorship 10904621138473266Thirasastr P, Sutton TL, Joseph CP, Lin H, Amini B, Mayo SC, Araujo D, Benjamin RS, Conley AP, Livingston JA, Ludwig J, Patel S, Ratan R, Ravi V, Zarzour MA, Nassif Haddad EF, Nakazawa MS, Zhou X, Heinrich MC, Somaiah NCancersOutcomes of Late-Line Systemic Treatment in GIST: Does Sequence Matter? Cancers (Basel). 2024 Feb 23; 16(5).Cancers (Basel)2024-02-23T00:00:002024Outcomes of Late-Line Systemic Treatment in GIST: Does Sequence Matter?true1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1Associate ProfessorAssociate Professortrue1Assistant ProfessorAssistant Professortrue1Assistant ProfessorAssistant Professor24046124Hayes-Jordan A, Green HL, Lin H, Owusu-Agyemang P, Fitzgerald N, Arunkumar R, Mejia R, Okhuysen-Cawley R, Mauricio R, Fournier K, Ludwig J, Anderson PAnnals of surgical oncologyComplete cytoreduction and HIPEC improves survival in desmoplastic small round cell tumor. Ann Surg Oncol. 2014 Jan; 21(1):220-4.Ann Surg Oncol2013-09-18T00:00:002013Complete cytoreduction and HIPEC improves survival in desmoplastic small round cell tumor.